| Gene symbol | IL12A | Synonyms | CLMF, IL-12A, NFSK, NKSF1, P35 | Type of gene | protein-coding |
| Chromosome | 3 | Map location | 3q25.33 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | interleukin 12A | ||||
| Gene symbol | IL12B | Synonyms | CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF, NKSF2 | Type of gene | protein-coding |
| Chromosome | 5 | Map location | 5q33.3 | dbXrefs | |
| Description | interleukin 12B | ||||
| GTO ID | GTC3043 |
| Trial ID | NCT05392699 |
| Disease | Advanced Solid Tumor |
| Altered gene | IL-12A|IL-12B |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA |
| Treatment | ABOD2011 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | An Open-blind Dose Escalation Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ABOD2011 in Patients With Advanced Solid Tumors Progressed After Standard Systemic Therapy |
| Year | 2022 |
| Country | China |
| Company sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
| Other ID(s) | ABOD2011-001 |
| Vector information | |||
|
|||
| Cohort1: ABOD2011_single dose | |||||||
|
|||||||
| Cohort2: ABOD2011_multiple dose | |||||||
|
|||||||